By Dhirendra Tripathi
Investing.com – Johnson & Johnson (NYSE:JNJ) stock was trading 0.6% lower in Tuesday’s premarket after the U.S. Food and Drug Administration warned the company’s Covid-19 vaccine raises the risk of a rare neurological condition.
The condition, known as Guillain-Barré syndrome, results in the body’s immune system attacking the nerves, causing temporary paralysis. Most people fully recover, but in some cases, the paralysis can be severe.
The FDA has found a few such cases among the millions administered the J&J shot.
According to a statement from the U.S. Center for Disease Control and Prevention, most of the cases were in men, many of whom were 50 or older, Reuters reported.
As per the FDA, 100 preliminary reports of GBS in the vaccine recipients include 95 serious cases that required hospitalization and one reported death.
According to Reuters, around 12.8 million people have received J&J's one-dose vaccine in the U.S.
J&J’s shot has had more than one hiccup in the past. There were cases of blood clotting but the FDA said the vaccine’s benefits outweighed the risks. There were also production problems at one of its plants in Baltimore, and theFDA asked the company to dump 60 million doses of its Covid-19 vaccine made at the site last month.